	US 12,146,157 B2
	Anti-PTK7 immune cell cancer therapy
Jonathan Alexander Terrett, Cambridge, MA (US); and Jason Sagert, Cambridge, MA (US)
Filed by CRISPR THERAPEUTICS AG, Zug (CH)
Filed on Nov. 7, 2019, as Appl. No. 16/677,207.
Claims priority of provisional application 62/910,586, filed on Oct. 4, 2019.
Claims priority of provisional application 62/756,638, filed on Nov. 7, 2018.
Prior Publication US 2020/0140815 A1, May 7, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/0783 (2010.01); A61K 35/17 (2015.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/40 (2006.01); C12N 15/11 (2006.01); C12N 15/86 (2006.01)

CPC C12N 5/0636 (2013.01) [A61K 35/17 (2013.01); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 14/70575 (2013.01); C07K 16/40 (2013.01); C12N 15/11 (2013.01); C12N 15/86 (2013.01); A61K 2039/505 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C12N 2750/14143 (2013.01)]

24 Claims

1. An engineered T cell comprising a nucleic acid encoding a chimeric antigen receptor (CAR) that binds protein tyrosine kinase 7 (PTK7), wherein the CAR comprises an ectodomain comprising an anti-PTK7 single-chain variable fragment (scFv) having the amino acid sequence of SEQ ID NO: 54 and a CD28 co-stimulatory domain.